ArticleDrug design, development and therapy2025
Development and Characterization of a Cationic Polyurethane Carrier for Enhanced Topical DNA Delivery.
Article in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Nucleic acids are increasingly being recognized for their potential as therapeutic agents for the treatment of a variety of pathologies, such as genetic diseases, viral infections, and cancer. However, the safe delivery of these negatively charged macromolecules to their intended sites of action remains a major challenge. Purpose: This study aimed to design and characterize cationic particles for use as nonviral vectors for nucleic acid delivery; another primary objective was to evaluate the biocompatibility between the particles and DNA. Methods: The particles were synthesized via a polyaddition process between isophorone diisocyanate and a mixture of polyethylene glycol and polycaprolactone diol. The structural characteristics were assayed using a variety of techniques, including measurements of pH, refractive index, and Zetasizer, drug release and penetration through an artificial membrane, SEM, FTIR and Raman spectroscopy, thermal analyses, cell viability, and in vivo evaluation of skin parameters. Results: The findings revealed that nearly neutral-pH particles were successfully synthesized, displaying a broad size distribution ranging from 400-900 nm, a prolonged release profile, and an encapsulation efficacy of 72.5%. Thermal analyses demonstrated that the samples remained stable at temperatures up to 200 °C, and the results of the spectroscopy, cell assay, and evaluations on mouse skin suggest that the obtained particles are safe for use as DNA carriers. Conclusion: Cationic polyurethane carriers present a potential alternative to the more established polyethylenimine. However, additional studies are necessary to fully assess the therapeutic effectiveness of these formulations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.